Five things for pharma marketers to know: Friday, April 29, 2016

1. Sales of Gilead Sciences' blockbuster hepatitis C drugs Harvoni and Sovaldi have started to slow down. The drugs generated $4.3 billion in sales in the first quarter of 2016, down $600 million from the fourth quarter of 2015. (Stat)

2. Drugmakers are placing billion-dollar bets on new cancer therapies. This week Sanofi made an unsolicited, $9.3 billion offer to purchase San Francisco-based Medivation and AbbVie announced it would pay $5.8 billion to acquire Stemcentrx. Medivation rejected Sanofi's offer. (WSJ)

3. Valeant disclosed a number of changes to its business, including new board members; restated results for Addyi, its sexual-desire drug for women, and Xifaxan, its irritable bowel syndrome drug; and additional investigations into its business and pricing practices. (Reuters)

4. AstraZeneca said it will cut $1 billion in costs, notably to commercial and manufacturing operations, and focus more on developing oncology drugs. (Reuters)

5. Public Citizen filed a lawsuit against the FDA, seeking to force the regulator to disclose additional information about the people who serve on its advisory committees. (Stat)